A highlight on Sonic hedgehog pathway

Gabriela Basile Carballo1,3, Jéssica Ribeiro Honorato1,2,3, Giselle Pinto Farias de Lopes2 and Tania Cristina Leite de Sampaio e Spohr1*

Abstract: Hedgehog (Hh) signaling pathway plays an essential role during vertebrate embryonic development and tumorigenesis. It is already known that Sonic hedgehog (Shh) pathway is important for the evolution of radio and chemo-resistance of several types of tumors. Most of the brain tumors are resistant to chemotherapeutic drugs, consequently, they have a poor prognosis. So, a better knowledge of the Shh pathway opens an opportunity for targeted therapies against brain tumors considering a multi-factorial molecular overview. Therefore, emerging studies are being conducted in order to find new inhibitors for Shh signaling pathway, which could be safely used in clinical trials. Shh can signal through a canonical and non-canonical way, and it also has important points of interaction with other pathways during brain tumorigenesis. So, a better knowledge of Shh signaling pathway opens an avenue of possibilities for the treatment of not only for brain tumors but also for other types of cancers. In this review, we will also highlight some clinical trials that use the Shh pathway as a target for treating brain cancer.

Keywords: Sonic hedgehog pathway, Canonical Shh signaling, Non-canonical Shh signaling, Clinical-trials, Brain tumors

Background
Hedgehog (Hh) is one of few of signaling pathways that is frequently used during development for intercellular communication. Hh is important for the organogenesis of almost all organs in mammals, as well as in regeneration and homeostasis. Further, Hh signaling is disrupted in diverse types of cancer [1, 2]. The vertebrate Hh signaling is not entirely dependent on an extremely specialized organelle, the primary cilium (PC), unlike other essential developmental signaling pathways. The PC is an organelle, microtubule-based, that emerges from the cell surface of most vertebrate cells. This organelle is important to process several cellular signals and/or extracellular environmental changes necessary for animal development, as Wingless (Wnt), Platelet-derived growth factor (PDGF), Shh, and Notch [3].

There are three mammalian Hh proteins, Shh, Indian-Hedgehog (Ihh), and Desert-Hedgehog (Dhh). Shh and Ihh have important, and sometimes coinciding, functions in several tissues. Shh has particularly marked roles in nervous system cell type specification and limbs patterning, whereas Ihh has important roles in skeletal development, mainly endochondral ossification. Dhh is restricted to the gonads including granulosa cells of ovaries and sertoli cells of testis [4–6]. The best-studied function of Shh, during mouse embryogenesis, is to instruct neural progenitors patterning, in which it is possible to distinguish six different cell types based on molecular markers, such as interneurons progenitors and motor neurons, that differentiate due to a gradient of Shh [7, 8].

Several evidences demonstrate that embryogenesis and tumorigenesis have common characteristics, where both processes depend on coordinated mechanisms of proliferation, differentiation and migration [9]. Vital signaling pathways for embryonic development and organogenesis are modulated in tumorigenesis. Aberrant activation of Hh signaling has been shown to be associated with the formation of brain tumors, as well as its cross talking with other pathways like transforming growth factor beta (TGFβs), Wnt, Notch and Shh [10–12]. Moreover, several studies have investigated the role of Hh-Gli (Gli means glioma-associated oncogene homologue) signaling in cancer initiating stem cells (CSCs) and suggested that it regulates self-renewal and tumorigenic potential [13]. This review focused on updating the role of these
molecules in brain tumorigenesis as well as suggesting new therapeutic strategies/clinical trials using the Shh pathway as a potential future treatment.

**Shh signaling pathway components in tumorigenesis**

The canonical pathway

Activation of Shh pathway can happen in two major ways: 1. canonical signaling: by ligand-dependent interaction or through receptor-induced signaling and 2. non-canonical signaling, when there’s a mechanism of activation downstream of smoothened (Smo) (Fig. 1) [14].

The Shh canonical signaling occurs when the glycoprotein Shh binds and inactivates the 12-transmembrane protein Patched (Ptch1). In the lack of the ligand Shh, the activity of the 7-transmembrane protein Smo is inhibited by Ptch1, so Shh protein binding Ptch1 regulates Smo activity [15, 16]. Smo is a GPCR-like (G protein–coupled receptor) protein, and the translocation into the cilia membrane is a requisite for Gli activation [3, 17]. In response to Shh signaling, Ptch1 inhibition of Smo at the PC is abolished, when Ptch1 is internalized and degraded [18]. So, after Ptch1 degradation, Smo accumulates at the PC where is activated and stabilized by initiating the Shh downstream signaling cascade [18].

This downstream signaling cascade results in the translocation of Gli family proteins to the nucleus that begins the transcription of target genes, including Ptch1 and Gli1, in a negative and positive feedback loop, respectively (Fig. 1) [14]. Furthermore, Gli translocation to the nucleus also induces protein modulation of Wnt and Noggin [16, 19, 20]. Patched 2 (Ptc2) is another receptor for Shh that shares approximately 54% homology with Ptc1. However, the expression and signaling of Ptc2 is different from Ptc1, having decreased ability to inhibit Smo in absence of Shh ligand [21].

The Gli1 gene was initially cloned as an amplified oncogene of a malignant glioma and then characterized as a transcription factor of the hedgehog signaling pathway [22, 23]. Three Gli proteins (Gli1, Gli2 and Gli3) are zinc-finger transcription factors and are expressed in vertebrates, in overlapping and partially redundant domains. These three proteins are Shh-dependent, where only Gli1 occurs as a full-length transcriptional activator, while Gli2 and Gli3 act as either a negative or positive regulators (Gli2A - Gli2 activated or Gli2R - Gli2 repressor and Gli3A - Gli3 activated or Gli3R - Gli3 repressor, respectively) of the pathway which is determined by post-transcriptional and post-translational processing [24, 25]. Moreover, the change of Gli3A to Gli3R form is favored with respect to Gli2. Consequently, Gli2 has mainly an activator transcriptional behavior, while Gli3 acts as a repressor [26]. It has already been demonstrated that Gli2 can accumulate in the primary cilium and controls transcriptional activation, in response to Shh ligand binding, overcoming thereby the negative regulation of Gli3 [27].

The Gli3 has also a very important function in regulating Shh signaling. Without Shh, Gli3 has a repressor form (Gli3R). When Shh binds to Ptc and activates Smo, Smo converts Gli3R into an activated form (Gli3A). So, Gli3 works as a transcriptional factor with a dual function. The ratio of Gli3R/Gli3A is directly related to the control of several processes during organogenesis, such as digit types and number [28, 29].

Shh signaling pathway can also be controlled by Suppressor of Fused (SUFU) (Fig. 2) [30]. SUFU is a negative regulator of the Shh signaling pathway, acting on the Gli transcription factors. When Shh ligand is not present, SUFU binds directly the Gli proteins and inhibits their translocation to the nucleus, preventing the pathway activation [31]. However, the specific mechanisms concerning Gli inactivation by SUFU are not completely understood, but the full-length Gli proteins are converted to a C-terminal shorten repressor form: Gli-R. This truncated form of Glis is then partially degraded after subsequent phosphorylation by glycogen synthase kinase 3 beta (GSK3β), casein kinase 1 (CK1) and protein kinase A (PKA) [26]. Gli proteins retained at the
Fig. 2 The non-canonical activation of Shh pathway. The non-canonical activation occurs through Gli-independent mechanisms and it can be of two types. A) Type I which modulates Ca\(^{2+}\) and actin cytoskeleton (left). When Shh binds the receptor Ptch, Smo is no longer inhibited and couple Gi proteins (G) and small GTPases RhoA and Rac1 activated. In addition, Smo stimulates calcium (Ca\(^{2+}\)) release from the endoplasmic reticulum (ER) and PLC-\(\gamma\)-catalyzed the opening of IP3-dependent channels by the generation of IP3. B) Type II which is independent on Smo. When Shh binds Ptch, the interaction of Ptch with cyclin B1 is disrupted, leading to an increase in cell proliferation and survival (right). (Diagrams by Carballo, VC). (Adapted from Robbins et al., 2012) [54]

Fig. 3 The crosstalk between Shh pathway and others. Shh signaling pathway can crosstalk with several pathways, especially EGF, Wnt and TGF-\(\beta\). Here we can observe the Shh signaling pathway in blue, the EGF pathway in orange, the Wnt pathway in, and TGF-\(\beta\) pathway in green. The crosstalk between these pathways and Shh occurs at different moments, and it becomes more important to understand this molecular interaction in order to search for new therapeutical drugs. (Diagrams by Carballo, VC). (Adapted from Matias et al., 2017; Berg and Soreide, 2012 and https://www.mycancergenome.org/content/molecular-medicine/pathways/TGF-beta-signaling) [128, 129]
cytoplasm by SUFU are then degraded or processed and thereby inhibiting Shh signaling [32]. When Gli-R moves to the nucleus, it represses SHH target genes including Ptch1 and Gli1 itself. When Shh pathway is activated, it is necessary that SUFU inhibition of Gli occurs by hyper-phosphorilation of SUFU [33]. Therefore, it has been previously demonstrated that several protein kinases, such as PKA and protein kinase C (PKC), CK1, mitogen activated protein kinase kinase (Mek1), GSK3, Phosphoinositide-3 kinase (PI3K), or dual specificity Yak1-related kinase (DYRK1) can modulate this pathway at several levels [33–39] (Fig. 2). This mechanism of regulation of the Shh pathway by ubiquitination-related posttranslational modifications of the Gli transcription factors leads to massive protein degradation or a proteasome-dependent proteolytic cleavage [40]. This process was first identified in Drosophila, but it was also demonstrated in vertebrates [41]. It is important to note that mutations in Ptch and SUFU, which are the negative regulators of Shh signaling, are linked to tumorigenesis, although the exact mechanism is unknown [42]. It was demonstrated in knockout mice, that the loss of SUFU is enough to activate the pathway without the support of the receptors [43, 44]. This constitutive Shh signaling activation in medulloblastoma (MB) is not sufficient to induce tumorigenesis, because a second tumor suppressor must be inactivated, such as p53 [45].

Besides ubiquitination, mainly of Gli3, to control Shh pathway, it was also demonstrated that Gli1 and Gli2 can be acetylated at lysine 518 and 757, respectively [46]. The mechanism of deacetylation of these proteins is mediated by the enzyme histone deacetylase 1 (HDAC1), which promotes transcriptional activation of the pathway. This activation is turned off by the degradation of HDAC1, which sustains a positive autoregulatory loop, when Shh is present. This degradation is mediated through an E3 ubiquitin ligase complex [46].

Shh signaling pathway is a valid therapeutic goal in a broad range of cancers, such as pancreas, prostate, breast and brain tumors. We focus here on brain tumors. The transcriptomics data on 149 clinical cases of The Cancer Genome Atlas-Glioblastoma (GBM) database showed a robust correlation between PTCH1 and GLI1 mRNA expression as an indication of the canonical Shh pathway activity in this malignancy. The expression of GLI1 mRNA varied in three orders of significance among the GBM patients of the same cohort, demonstrating a single continuous distribution different from the discrete high/low-GLI1 mRNA expressing clusters of MB [47]. Furthermore, it has already been well-established that tumor microenvironment plays an important role in controlling GBM pathology and their drug-resistance mechanisms [48]. Cells from the tumor microenvironment usually secrete inflammatory cytokines, growth factors [49–51] and other proteins that can activate Shh signaling in a typical or atypical manner (canonical or non-canonical) [52]. It was demonstrated that in the tumor microenvironment the endothelial cells provide Shh to activate the Hh signaling pathway in GBM cells, thereby promoting glioma stem cells (GSC) properties and tumor propagation [53].

**Non-canonical Shh signaling**

The “non-canonical Shh signaling” usually occurs through Gli-independent mechanisms. The Gli-independent mechanisms include two types: Type I is downstream of Smo, which modulates Ca²⁺ and actin cytoskeleton and type II is independent of Smo and increases cell proliferation and survival [54]. The non-canonical Shh signaling can regulate chemotaxis and cell migration through actin rearrangement. Additionally, it can stimulate cell proliferation via calcium-induced extracellular signal-regulated kinases (ERK) activation and activate Src family kinase, which is required axon guidance [54–56].

Some studies emerged mainly in tumor cells concerning the non-canonical Shh signaling in the last ten years. However it has not been completely elucidated how Smo selects between canonical or non-canonical routes. Usually the non-canonical route occurs when Smo couples to Gai in vertebrates and modulates Ca²⁺ flux, Ras homolog gene family, member A (RhoA) and Rac activation and Warburg-like metabolism [56–58].

Interestingly, it was first believed that only Shh canonical signaling occurs when Smo enters the PC [59], and if Smo does not route through PC, it signals through a non-canonical pathway [17]. However, it was recently demonstrated that non-canonical Shh signaling leads to acetylation of α-tubulin via Smo-mediated calcium which increases in a primary cilia-dependent manner in mouse embryonic fibroblasts [17]. There are rare studies of this type of signaling associated with tumorigenesis and none with brain tumors. A ligand-independent Smo mutant resulted in tumors over-expressing Shh that show pronounced chromosomal instability and smoothened-independent up-regulation of Cyclin B1, a putative non-canonical branch of the Shh pathway in lung cancer. These results strongly support an autocrine, ligand-dependent model of Shh signaling in Small Cell Lung Cancer tumorigenesis and explain a new role for non-canonical Shh signaling through the induction of chromosomal instability [60]. Moreover, Hh signaling has an important role on the switch of hypoxia-induced pancreatic cancer epithelial to mesenchymal transition and invasion in a ligand-independent manner [61].

Recently, it was demonstrated that the intraflagellar transport protein 80 (IFT80) promotes Hh canonical signaling via activation of Hh-Smo-Ptch1-Gli signaling pathway...
during osteoblasts (OBs) differentiation. On the other hand, when this occurs, the non-canonical Hh signaling is inhibited via Hh-Smo-Goi-RhoA-stress fibre signalling, demonstrating that non-canonical Hh signaling negatively regulates OBs differentiation [62]. Moreover, this study demonstrated that at least in OBs differentiation and bone formation, IFT80 is essential for the balance of the non-canonical and canonical Hh signaling pathways [62].

However, the researchers are still unveiling the mystery of the non-canonical Smo signaling axis, as well as how Smo selects between canonical and non-canonical routes.

**Shh interaction with others pathways**

It is already known that Shh signaling is very important for embryonic development and in adults, deregulation or mutation of this pathway plays an important role in both differentiation and proliferation, inducing tumorigenesis [63, 64]. Furthermore, CSCs follow the same pathways than normal stem cells such as Wnt, Shh, Notch and others and are also present during embryonic development, organogenesis and tumorigenesis [10–12].

Emerging evidence suggests that Shh signaling pathway can interact with other signaling components, such as TGF-β, epidermal growth factor receptor (EGFR), KRas, PKA, Notch, and Wnt/β-catenin (Fig. 3) [65, 66]. Furthermore, it has been suggested that more than one of these pathways are active, in different types of tumors, at the same time [16].

The Shh and Wnt pathways could interact in two ways: 1. through Gli1 and Gli2, which have been shown to regulate positively the expression of secreted frizzled-related protein-1 (sFRP-1) and thus inhibiting Wnt ligands and/or their receptors [67] and 2. through downstream GSK3β (an essential component of complexes that inhibit Shh and WNT morphogenetic pathways) [68]. GSK3β, can act as a positive regulator of Shh signaling by phosphorylating SUFU and promoting the release of SUFU from Gli, at least when the pathway is active [69]. It has already been demonstrated that in mice without normal APC function (citoplasmatic degradation and nuclear exporting of β-catenin) that SUFU negatively regulates Tcf-dependent transcription by reducing nuclear β-catenin levels [70]. So, Shh can regulate Wnt signaling. This crosstalk between Shh and Wnt has also been demonstrated in medulloblastoma cells, where the loss of SUFU activates both pathways, inducing excessive proliferation and tumorigenesis [71]. Besides, Wnt signaling can also increase Shh pathway activity, as β-catenin may potentially affect the Gli1 transcriptional activity via TCF/LEF in an independent manner [66]. Interestingly, in gastric cancer, the Shh signaling pathway activation seems to be inversely correlated with the level of Wnt pathway activation. It was observed that Gli1 overexpression suppressed Wnt transcriptional activity, nuclear β-catenin accumulation and proliferation of gastric cancer cells [72].

It is well established that aberrant RAS activation has a protagonist role in tumorigenesis, and activating RAS mutation occurs in 30% of all human cancers [73]. It has been demonstrated that activation of the RAS/MAPK pathway (KRAS), induced by divers upstream signals and converging at the level of Gli transcription factors, is important in promoting cancer development during pancreatic tumorigenesis [74]. Another pathway that has been demonstrated to interact with Shh is the ERK signaling pathway, which controls Gli transcription factor function in Shh signaling, when stimulated by exogenous ligands (like basic fibroblast growth factor -bFGF) [39].

In addition to Wnt/β-catenin and KRAS, TGF-β/TGF-βR, EGFR, and platelet-derived growth factor receptor α (PDGFαRα) can also cooperate with the canonical Shh pathway [39, 66, 75–78]. There is an important increase in Gli1 and Gli2 expression induced through the activation of TGF-β/TGF-βR/Smads in pancreatic cell lines. Furthermore, these cells were resistant to Shh inhibition, but the pharmacologic blockade of TGF-β signaling leads to repression of cell proliferation accompanied by a reduction in Gli2 expression [79].

Another signaling pathway that crosstalk with Shh and contributes to tumorigenesis is EGFR signaling. The stimulation of EGFR/RAS/RAF/MEK/ERK in different cancer cell lines such as gastric, and pancreatic cancer cell lines and was able to activate the Gli transcription factor and selective transcriptional modulation of Gli target gene expression [76–78, 80]. However, it was observed in MB cells, a crosstalk mechanism where EGFR signaling silences proteins acting as negative regulators of Hh signaling, as an ERK and AKT-signaling independent method. Reciprocally, a high-level synergism was also observed, due to a significant and strong up-regulation of several canonical EGF-targets. Synergistic outcomes between EGFR and Hh signaling can selectively promote a shift from a canonical HH/GLI profile to a gene profile specific target modulated. It indicates that there are more diffuse, yet context-dependent (i.e. cancer-dependent) interactions, between growth factor receptors and HH/GLI signaling in human tumorigenesis [81].

So, it is becoming more and more evident that the integration of these signaling pathways, which are important for embryonic morphogenesis, may support a more malignant behavior by tumor cells and consequently maintain the tumorigenesis of diverse aggressive tumors, such as pancreas, prostate, breast and brain [78, 80]. The need to understand the role of these pathways in tumorigenesis is becoming increasingly evident, mainly the molecular crosstalk between them, as it is an important consideration for
the development of HH-targeting agents and the appropriate selection of a class of inhibitors for therapeutic intervention [82]. Furthermore, it is valid to be proposed in the future treatments of Shh-dependent tumors using inhibitors of Akt, PI3K, MEK, ERK, Wnt, EGFR and TGF-β [38, 66, 78–80].

Hh inhibitors and clinical trials

*The importance of stem cells in brain tumors*

Nowadays, several studies support the hypothesis that malignant tumors are initiated and maintained by CSCs. Although the origin of the CSCs in human tumors is not fully understood, it is already well established that these cells are responsible for the chemo and radioresistance of the most malignant tumors [49, 50]. The recurrence of the tumor is usually due the existence of these cells in the tumor bulk [49, 50]. Moreover, studies have demonstrated that CSCs could de-differentiate from a more differentiated cancer cell present in the tumor mass that acquires self-renewal properties, clonal tumor initiation capacity and clonal long-term repopulation potential, perhaps as a result of epithelial-to-mesenchymal transition (EMT) [83–85].

The hypothesis that the existence of CSCs initiates malignant tumor came from the observation that tumor cells, like adult tissues, originate from cells that can self-renew. Furthermore, that these cells also are able to differentiate into cell forming the tumor bulk [86]. In the adult tissue, these cells are the adult stem cells that are tissue-specific and multipotent, being able to differentiate between all cell types of the tissue of origin [86].

In the adult brain, it is already well established that the existence of a neurogenic niche, which is extremely dynamic and complex microenvironment where new glial cells and neurons are generated when necessary from the stem or progenitor cells [87]. This neurogenic niche has a very important role, as it provides signals that regulate whether the stem cells should differentiate, remain quiescent, or actively divide, controlling the self-renewal properties in this way and maintaining neural stem/progenitor cell populations [87]. These neural stem cells (NSCs) are found in two main niches in adult brain, in the lateral ventricles (ventricular-subventricular zone (V-SVZ)) and in the hippocampus (subgranular zone (SGZ)), and these microenvironments ensure the self-renew and multipotent properties [88, 89].

It is interesting to note that Shh is very important for determining cell fate and patterning during embryonic development, having a mitogenic effect on proliferative cells throughout development [90]. Recently it was demonstrated that in the adulthood, the level of Shh signaling pathway activation played an important role to regulate the balance between quiescent and activated NSCs. Moreover, when the Shh pathway was genetically activated the number of quiescent NSCs increased and the pool of activated NSCs decreased [91]. However, there was an initial transitory period over the short term when activated NSCs are actively proliferating, apparently when their G1 and S-G2/M phases were short [91].

Taking into account that in GBM, the Shh pathway is usually upregulated, affecting GBM CSC proliferation and self-renewal [87, 92], this discovery opened an avenue for clinical trials that managed not only to stop the tumor to growth but also the tumor to relapse after surgery.

*The importance of Shh and MGMT interaction in clinical trials*

Nowadays, the standard treatment for most brain tumors comprises resection of the majority of the tumor mass, followed by chemo- and radiotherapy [49, 93], being Temozolomide (TMZ) and radiotherapy being the gold standard treatment [94]. TMZ is an alkylating agent prodrug, and its effect on tumor cells is to methylate the O6 residues of guanine preventing DNA duplication during cell proliferation and inducing cell death and apoptosis [95]. However, the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT) is able to reverse the effects of alkylating agents as TMZ [96–98]. The MGMT promoter methylation is directly related to patient’s prognosis, as low promoter methylation status induces a high MGMT expression and a shorter survival due to a remarkable chemoresistance. On the other hand, a higher promoter methylation status predicts a good response to TMZ chemotherapy, as the MGMT enzyme is downregulated, resulting in longer survival for the patients [99, 100]. Therefore, studies are being done in order to control and impairs the MGMT enzyme activity in chemoresistant tumors It is interestingly to note that many DNA repair proteins could be potential targets for inhibiting cancer cells without affecting normal cells; as they usually are upregulated in several chemoresistant cells and cancers [101].

The most malignant tumors are also highly mutated and present CSCs, which make them difficult to treat. So efforts are being made in order to bypass the chemoresistance in tumors. As written above, the Shh pathway is upregulated in CSCs [87, 102]. Moreover, these cells express also usually high levels of MGMT, and therefore they are involved in chemotherapy resistance and are responsible for tumor recurrence [103]. Emerging evidences are demonstrating that Shh signaling pathway could regulate MGMT expression and chemoresistance to TMZ in human GBM. Moreover, this regulation occurred independently from MGMT promoter methylation status, offering a probable target to reestablish chemosensitivity to TMZ in tumor that developed chemoresistance [104]. Furthermore, it is believed that Gli1 expression is also responsible for chemoresistance in gliomas and that it’s overexpression is related to tumor recurrence after treatment. So in the
other hand, when Shh pathway is inhibited, the sensitivity to chemotherapy improves by down-regulating many genes related to apoptosis, cell survival, multi-drug resistance, and especially MGMT. Interestingly, the group did molecular analyses of the patient’s tumor specimens obtained before treatment which suggested activation of Shh pathway, as there was a high expression of Hh target genes including GLI1, PTCH1, PTCH2 and sFRP1. So, the treatment resulted in rapid regression of the tumor and reduction of symptoms, but unfortunately, this effect was transient and the patient died after five months of treatment. It was observed that the Hh pathway inhibition with GDC-0449 induced the malignant transformation in MB which induced the tumor regrowth and the rapid progress of the disease.

Only in 2012, the US Food and Drug Administration (FDA) approved GDC-0449 as a standard therapy in patients with locally advanced and metastatic BCC. Then few phase I and II clinical trials emerged with the objective to define the pediatric maximum tolerated dose and the efficacy of GDC-0449 in SHH-MB. Some studies evaluated the use of GDC-0449 in combination with TMZ. The studies were performed through the Pediatric Brain Tumor Consortium. These were phase II studies which evaluated the efficacy of GDC-0449 in younger patients, as well as in adult patients with recurrent or refractory MB. Many other collaborative studies using GDC-0449 are still ongoing which directs therapy based on both clinical and molecular risk stratification (see Table 2 and see www.clinicaltrials.gov). GDC-0449 has an advantage for the use in clinical trials since it has low toxicity and high specificity for the Shh pathway. Additionally, this drug may also be used together with other pathway inhibitors or chemotherapy. Moreover, GDC-0449 usually is well tolerated because of a lack of Smo receptor in most normal tissues. It is believed that the use of Shh pathway inhibitors in MB treatment may offer an adequate therapeutic option. However, it is important to note that, as Shh pathway is very important during development, the adverse effect of blocking Shh pathway in prepubescent children is not completely understood. Recently a study demonstrated that the use of GDC-0449 in pediatric oncologic patients induces short stature and growth abnormalities as they developed physical fusion. So, the use of Hh inhibitors in skeletally immature patients should be widely discussed and may be limited to those patients whom treatment options are limited or absent.

**Gli-based inhibitors**

Shh-MBs as GBMs are highly mutated tumors, and it is not uncommon for those tumors to demonstrate primary
| Compound | Where it acts |
|----------|---------------|
| 3H8, 6D7 (antibody) | Shh pathway inhibitor |
| Cyclopamine | Smo inhibitor |
| 5E1 Antibody | Shh pathway inhibitor |
| Isoflavon (Genistein) | Shh pathway inhibitor |
| Curcumin | Gli 1 inhibitor |
| Resveratrol | Gli 1 inhibitor |
| Epigallocatechin-3-gallate | Gli 1 inhibitor |
| Physalin B and Physalin F | Gli 1 inhibitor |
| Jervine | Smo inhibitor |
| Zerumbone | Gli 1 inhibitor |
| Staurosorpinone | Gli 1 inhibitor |
| Vitamin D3 | Smo inhibitor |
| GDC-0449 (Vi sm odegib/Erivedge™) | Smo inhibitor |
| IPI-926 (Saridegib) | Smo inhibitor |
| NVP-LDE225 (Erismodegib) (Sonidegib) | Smo inhibitor |
| PF-04449913 (Glasdegib) | Smo inhibitor |
| BRD-6851 | Smo inhibitor |
| LY2940680 | Smo inhibitor |
| MK-5710 | Smo inhibitor |
| SEN450 | Smo inhibitor |
| PF-5274857 (A-116) | Smo inhibitor |
| MRT-10 and MRT-14 | Smo inhibitor |
| TAK-441 | Smo inhibitor |
| SANT1, SANT2, SANT3, SANT4, SANT74 and SANT75 | Smo inhibitor |
| MS-0022 | Smo inhibitor |
| Arsenic Trioxide (ATO) | Gli 1 inhibitor |
| Sodium Arsenite | Gli 1 inhibitor |
| HPI-1, HPI-2, HPI-3 and HPI-4 | Gli inhibitors |
| AKI0532 | Probably Smo inhibitor |
| Itraconazole | Smo inhibitor |
| GANT 58, GANT 61 | Gli 1 inhibitor |
| KAAD-Cyclopamine | Smo inhibitor |
| Cur-61,414 | Smo inhibitor |
| Robotnikinin | Shh pathway inhibitor |
| SAG | Smo inhibitor |
| Purmorphamine | Smo inhibitor |
| BMS-833923 (XL139) | Smo inhibitor |
| LY2940680 (Taladegib) | Smo inhibitor |
| MRT-92 | Smo inhibitor |
| PF-5274857 | Smo inhibitor |
| LEQ506 | Smo inhibitor |
| RU-SKI 43 | Shh pathway inhibitor |
| Imiquimod | Shh pathway inhibitor |
| Patidegib | Shh pathway inhibitor |
resistance to SMO inhibition, as they present alterations in downstream SHH pathway genes such as SUFU, GLI2, or MYCN [125]. As described above, it is typical for those tumors to acquire secondary resistance to Shh inhibition, and in this case, a Shh inhibition monotherapy is not efficient [117]. This is why, several pharmaceutical companies such as Exelixis/Bristol-Myers Squibb, Novartis, Infinity, and Pfizer developed alternative Shh antagonists that act directly in Gli (see Table 1). Some of these inhibitors are already being tested in the brain and central nervous system tumors as coadjuvant therapy with TMZ (see Tables 2 and 3 and www.clinicaltrials.gov).

So, besides GDC-0449, NVPLDE-225 and BMS-833923 (XL139) were also tested in brain tumors. There were some phase I and phase II clinical trials completed with the purpose of testing the efficacy tolerability, pharmacokinetics, pharmaco-dynamics, and safety of these drugs orally [65].

Another drug that is being tested for gliomas in phase I and II clinical trials is the arsenic trioxide (ATO). ATO is an FDA-approved drug that has been shown to inhibit Gli-dependent growth in MB mouse model, which was first used for the treatment of patients with acute promyelocytic leukemia (APL) [126]. Recently, a study demonstrated that apparently, the treatment of patients in combination with ATO, TMZ, and radiation does not improve the overall outcome in GBM patients; however, it might have some benefit in anaplastic astrocytoma patients [127].

Most of Hh inhibitors that have entered clinical trials targeted Smo, although several mechanisms of resistance to Smo inhibitors have been identified. Therefore, the discovery of new Hh pathway inhibitors may be crucial to bypass these resistance mechanisms and control tumorigenesis.

Conclusions

The Shh pathway is a well-established pillar of neural development and cancer cells use this mechanism to resist therapy and recur. The Shh pathway is thought to be very simple, as it usually signals canonically through Gil proteins; however, the shh pathway can be very complex, as demonstrated by the emerging evidence. Moreover, this pathway can not only be controlled through several mechanisms and molecules, such as Gil2R and Gil3R, Carballo et al. Cell Communication and Signaling (2018) 16:11 Page 9 of 15
| Study | ClinicalTrials.gov Identifier | Sponsor | Tumor | Phase | Shh Drug inhibitor | Where it acts | Outcome of the clinical trials |
|-------|---------------------------------|---------|-------|-------|-------------------|---------------|--------------------------------|
| Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors | NCT00024258 | Memorial Sloan Kettering Cancer Center Collaborator: National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | Phase 2 | arsenic trioxide | Gli 1 inhibitor | Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
| Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma | NCT00720564 | City of Hope Medical Center Collaborator: National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | Phase 1 | arsenic trioxide | Gli 1 inhibitor | No Study Results Posted |
| Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas | NCT00095771 | Sidney Kimmel Comprehensive Cancer Center Collaborator: National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | Phase 1 | arsenic trioxide | Gli 1 inhibitor | No Study Results Posted |
| Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma | NCT00185861 | Stanford University Collaborators: Cephalon CTI BioPharma | Brain Cancer | Phase 1 | arsenic trioxide | Gli 1 inhibitor | No Study Results Posted |
| Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | NCT00045565 | National Cancer Institute (NCI) | Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma | Phase 1 | arsenic trioxide | Gli 1 inhibitor | No Study Results Posted |
| Curcumin Bioavailability in Glioblastoma Patients | NCT01712542 | Johann Wolfgang Goethe University Hospital | Glioblastoma | Early Phase 1 | Curcumin | Shh inhibitor | No Study Results Posted |
| GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment | NCT00822458 | National Cancer Institute (NCI) | Recurrent Childhood Medulloblastoma | Phase 1 | GDC-0449 (vismodegib) (Erivedge) | Smo inhibitor | No Study Results Posted |
| GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | NCT00980343 | National Cancer Institute (NCI) | Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor | Phase 2 | GDC-0449 (vismodegib) (Erivedge) | Smo inhibitor | The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo. |
| Study                                                                 | ClinicalTrials.gov Identifier | Sponsor                                      | Tumor                                 | Phase | Shh Drug inhibitor | Where it acts                                                                 | Outcome of the clinical trials                                      |
|---------------------------------------------------------------------|-------------------------------|----------------------------------------------|---------------------------------------|-------|-------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma | NCT01239316                  | National Cancer Institute (NCI)              | Recurrent Childhood Medulloblastoma   | Phase 2 | GDC-0449 (vismodegib) (Erivedge) | Smo inhibitor                                                                  | Resulted in the following paper: Robinson et al., 2015               |
| Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma | NCT00939484                  | National Cancer Institute (NCI)              | Adult Medulloblastoma                 | Phase 2 | GDC-0449(vismodegib) (Erivedge) | Smo inhibitor                                                                  | Resulted in the following paper: Robinson et al., 2015               |
| Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma | NCT01774253                  | Giselle Sholler Collaborators: Spectrum Health Hospitals Phoenix Children's Hospital | Pontine Glioma                        | Phase 2 | GDC-0449(vismodegib) (Erivedge) | Smo inhibitor                                                                  | Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data Posted |
| Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation | NCT00336531                  | Samsung Medical Center                       | Neuroblastoma Brain Tumor Retinoblastoma | Phase 4 | itraconazole       | downregulation in GLI                                                          | No Study Results Posted                                               |
| A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors | NCT01106508                  | Novartis Pharmaceuticals                     | Recurrent or Refractory Medulloblastoma | Phase 1 | LEQ506             | Smo inhibitor                                                                  | No Study Results Posted                                               |
| Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308                  | Novartis Pharmaceuticals                     | Medulloblastoma                       | Phase 1 | LDE225(Sonidegib)   | Smo inhibitor                                                                  | No Study Results Posted                                               |
| An East Asian Study of LDE225                                      | NCT01208831                  | Novartis Pharmaceuticals                     | Medulloblastoma                       | Phase 1 | LDE225              | Smo inhibitor                                                                  | No Study Results Posted                                               |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | NCT01125800                  | Novartis Pharmaceuticals                     | Medulloblastoma Rhabdomyosarcoma Neuroblastoma Hepatoblastoma Glioma Astrocytoma | Phase 1 | LDE225 (Sonidegib) | Smo inhibitor                                                                  | Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | NCT01576666                  | Novartis Pharmaceuticals                     | Recurrent Glioblastoma Multiforme     | Phase 1 | LDE225 (Sonidegib) | Smo inhibitor                                                                  | No Study Results Posted                                               |
| A Phase II Study of Oral LDE225 in Patients With Hedge-            | NCT01708174                  | Novartis Pharmaceuticals                     | Medulloblastoma                       | Phase 2 | LDE225 (Sonidegib) | Smo inhibitor                                                                  | Other disclosure agreement that restricts the right of               |
SUFU and PtcH, which are components of the pathway, but also through posttranslational modifications, such as ubiquitination and acetylation. Several reports demonstrated that Shh could also signal through a non-canonical route; however, it is still a mystery how the cells select between canonical and non-canonical routes. Shh pathway can also interact with other signaling components that are important during embryonic development and tumorigenesis, such as TGF-β, EGFR, and Wnt. Cross-talking between these pathways and Shh signaling plays a pivotal role in the preservation of CSCs postulated to have intrinsic resistance to chemotherapy. So, a better understanding of the mechanisms is involved in the interaction between Shh pathway and these pathways open a huge window of opportunities for the development of new therapeutic drugs for multiple cancers. Moreover, the inhibition of Shh signaling components may prove to be key to resistance and potential therapeutic targets to GBM and MB. The CSC hypothesis provides an explanation for the heterogeneity and recurrence of these tumors, and the Shh signaling pathway plays an important role in the maintenance of these cells. However, we believe that the best way to control the tumor recurrence is combining Shh antagonist with conventional therapies that are actually used in the clinic. Nowadays, the primary target used for development of Shh-pathway inhibitors in clinical trials is SMO, and there are several clinical trials for different types of brain tumors ongoing. So, current clinical trials offer a great outlook to overcome brain tumor. But, we still believe that more researchers must be conducted, as unfortunately we did not reach the cure for most of the cancers, such as GBMs and MBs, that are very aggressive.

**Abbreviations**

APL: Promyelocytic leukemia; ATO: Arsenic trioxide; BCC: Basal cell carcinoma; bFGF: Basic fibroblast growth factor; CK1: Casein kinase 1; CSCs: Cancer initiating stem cells; Dhh: Desert-Hedgehog; Dyrk1: Dual specificity Yak1-related kinase; EGFR: Epidermal growth factor receptor; EMT: Epithelial-to- mesenchymal transition; ERK: Extracellular signal-regulated kinases; FDA: Food and Drug Administration; GBM: Glioblastoma; GDC-0449: Vismodegib; Gl1: Glioma-associated oncogene homolog 1; Gl2A: Gl2 activated; Gl2R: Gl2 repressor; Gl3A: Gl3 activated; Gl3R: Gl3 repressor; GPCR: G protein–coupled receptor; GSC: Glioma stem cells; GSK3: Glycogen synthase kinase 3; HDAC1: Histone deacetylase 1; Ihh: Hedgehog; IFT80: Intraflagellar transport protein 8; Ihh: Indian-Hedgehog; MB: Medulloblastoma; MeK1: Mitogen activated protein kinase; MGMT: O-6-methylguanine-DNA methyltransferase; NSCs: Neural stem cells; NVPLDE-225: Erismodegib or Sonidegib or Odomzo; Obs: Osteoblasts; Pc: primary cilium; PDGF: Platelet-derived growth factor; PDGFRA: Platelet-derived growth factor receptor α; P38K: Phosphoinositide-3 kinase; PKA: Protein kinase A; PKC: Protein kinase C; PtcH1 and 2: Patched 1 and 2; Patched 1 and Patched 2; RhôA: Ras homolog gene family, member A; sFRP-1: Secreted frizzled-related protein-1; SGZ: Subgranular zone; Shh: Sonic-Hedgehog; Smo: Smoothened; SUFU: Suppressor of fused; TGFβ: Transforming growth factor beta; TMZ: Temozolamide; V-SVZ: Ventricular-subventricular zone; Wnt: Wingless

**Acknowledgements**

We thank to Professor Vivaldo Moura Neto for careful reading the manuscript.

**Funding**

This work was supported by the National Institute for Translational Neuroscience (INCT) of the Ministry of Science and Technology; Brazilian Federal Agency for the Support and Evaluation of Graduate Education (CAPES) of the Ministry of Education; National Council for Scientific and Technological Development (CNPq); Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro Carlos Chagas Filho Research Support Foundation (FAPERJ); Ary Frauzino Foundation for Cancer Research and Pró-Saúde Beneficência Beneficiante de Assistência Social e Hospitalar.

**Availability of data and materials**

Not applicable.

**Authors’ contributions**

All Authors participated in the elaboration of the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Laboratory de Biomedicina do Cérebro, Instituto Estadual do Cérebro Paulo Niemeyer (IECPN), Secretaria de Estado de Saúde, Rua do Rezende 156, Centro, Rio de Janeiro CEP. 20320–024, Brazil. 2 Laboratório de Hemato-Oncologia Celular e Molecular, Programa de Pesquisa em Hemato-Oncologia Molecular, Coordenação de Pesquisa, Instituto Nacional de Câncer (INCA), RJ, Brazil. 3 Programa de Pós-Graduação em Anatomia Patológica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Received: 5 December 2017 Accepted: 16 February 2018
Published online: 20 March 2018

References
1. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-Oncology. 2001;3:152–8.
2. Bangs F, Anderson KV. Primary cilia and mammalian hedgehog signaling. Cold Spring Harb Perspect Biol. 2017;9.
3. Goetz SC, Anderson KV. The primary cilium: a signalling centre during vertebrate development. Nat Rev Genet. 2010;11:331–44.
4. Bitgood MJ, Shen L, McMahon AP. Sertoli cell signaling by desert hedgehog. Dev Biol. 2000;219:285–304.
5. Yau HH, Whoriskey K, Capel B. Desert hedgehog/patched 1 signaling specifies fetal Leydig cell fate in testis organogenesis. Genes Dev. 2002;16:1433–40.
6. Wijgerde M, Ooms M, Hoogerbrugge NW, Grootegoed JA. Hedgehog signaling in mouse oviduct: Indian hedgehog and desert hedgehog from granulosa cells induce target gene expression in developing theca cells. Endocrinology. 2005;146:5358–66.
7. Briscoe J, Ericson J. Specification of neuronal fates in the ventral neural tube. Curr Opin Neurobiol. 2001;11:43–9.
8. Dessaud E, McMahon AP, Briscoe J. Pattern formation in the vertebrate neural tube: a sonic hedgehog morphogen-regulated transcriptional network. Development. 2008;135:2489–503.
9. Ma Y, Zhang P, Wang F, Yang J, Yang Z, Qin H. The relationship between early embryo development and tumourigenesis. J Cell Mol Med. 2010;14:2697–701.
10. Roth W, Wild-Bode C, Platten M, Grimmel M, Melkonyan HS, Dihgans J, Weller M. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene. 2000;19:420–8.
11. Golestanian N, Mishra B, TGF-beta, neuronal stem cells and glioblastoma. Oncogene. 2005;24:5722–28.
12. Lima FR, Kahn SA, Soletti RC, Biasoli D, Alves T, da Fonseca AC, Garcia C, Pietrosanti L, De Smaele E, Ferretti E, Miele E, et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochim Biophys Acta. 2012;1826:338–45.
13. Ruiz i, Altaba A, Mas C, Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol. 2007;17:438–47.
14. Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the sonic hedgehog signaling pathway in cancer: beyond smoothened. Oncotarget. 2015;6:9890–913.
15. Gogermer K, Grimm T, Kogermer L, Krause D, Unden AB, Sandstedt B, Toftgard R, Zaphiropoulos PG. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of GLI-1. Nat Cell Biol. 1999;1:312–9.
16. Humke EW, Dorn KV, Milenkovic L, Scott MP, Rohtagi R. The output of hedgehog signaling is controlled by the dynamic association between suppressor of fused and the Gli proteins. Genes Dev. 2010;24:670–82.
17. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007;104:8455–60.
18. Kaesler S, Luscher B, Ruther U. Transcriptional activity of GLI1 is negatively regulated by protein kinase a. Biol Chem. 2000;381:545–9.
19. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 2002;7:515–25.
20. Archer TC, Weeraratne SD, Pomeroy SL. Hedgehog-GLI pathway in cancer: beyond smoothened. Oncogene. 2003;22:5154–65.
21. Kandel ER, Schwartz JH, Jessell TM. Principles of neural science. 4th ed. New York: McGraw-Hill, Health Professions Division; 2000.
22. Rahnama F, Toftgard R, Zaphiropoulos PG. Distinct roles of PTCH2 splice variants in hedgehog signalling. Biochem. J. 2004;373:83–94.
23. Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O’Brien SJ, Wong AJ, Vogelstein B. Identification of an amplified, highly expressed gene in a human glioma. Science. 1987;236:70–3.
24. Ruiz i, Altaba A, Mas C, Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol. 2007;17:438–47.
25. Sasaki H, Nishizaki Y, Hui C, Nakafuku M, Kondoh H. Regulation of GLI2 and GLI3 activities by an amino-terminal repression domain: implication of GLI2 and GLI3 as primary mediators of Shh signaling. Development. 1999;126:3915–24.
26. Teplug S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta. 2010;1805:181–208.
27. Kim J, Kato M, Beachy PA. GLI2 trafficking links hedgehog-dependent activation of smoothened in the primary cilium to transcriptional activation in the nucleus. Proc Natl Acad Sci U S A. 2009;106:21665–70.
28. Luntting Y, Dahn RD, Li Y, Fallon JF, Chiang C, Shih and G3 are dispensable for limb skeleton formation but regulate digit number and identity. Nature. 2002;418:799–83.
29. Hui CC, Angers S. Gli proteins in development and disease. Annu Rev Dev Biol. 2011;27:13–37.
30. Gonnissen A, Isebaert S, Haustermans K. Targeting the hedgehog signaling pathway in cancer: beyond smoothened. Oncotarget. 2015;6:13990–913.
31. Golestaneh N, Mishra B. TGF-beta, neuronal stem cells and glioblastoma. Oncogene. 2005;24:5722–28.
32. Ruiz i, Altaba A. Catching a GLI-mpse of hedgehog. Cell. 1997;90:913–6.
33. Sasaki H, Nishizaki Y, Hui C, Nakafuku M, Kondoh H. Regulation of GLI2 and GLI3 activities by an amino-terminal repression domain: implication of GLI2 and GLI3 as primary mediators of Shh signaling. Development. 1999;126:3915–24.
34. Denef N, Neubuser D, Perez L, Cohen SM. Hedgehog induces opposite changes in turnover and subcellular localization of patched and smoothened. Cell. 2000;102:521–31.
35. Dahmane N, Ruiz i, Altaba A. Sonic hedgehog regulates the growth and patterning of the cerebellum. Development. 1999;126:3089–100.
Cullin3-RENKSTD1 ubiquitin ligase interplays regulate hedgehog signalling through Glh acetylation. Nat Cell Biol. 2010;12:132–42.

47. Chandra V, Das T, Gulati P, Biswas NK, Rote S, Chatterjee U, Ghosh SN, Deb S, Saha SK, Chowdhury AK, et al. Hedgehog signalling pathway is active in GBM with Gli1 mRNA expression showing a single continuous distribution rather than discrete high/low clusters. PLoS One. 2015;10:e016390.

48. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2012;60:502–14.

49. Dubois LG, Campanati L, Rigby C, D’Andrea-Meira I, Spoth TC, Porto-Carreiro I, Pereira CM, Balca-Silva J, Kahn SA, DosSantos MF, et al. Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci. 2014;8:418.

50. Moura Neto V, Campanati L, Pereira CM, Freitas C, Coelho-Aguiar J, Tavares AL, SPOHR TCS, Aguiar KA, Kahn SA, Matus O, et al. Glioblastoma: a hidden side of the astrocyte. In: Gliona Cell Biology (Mentlein ASaR ed., vol. 1. Vienna: Springer Netherlands Vienna; 2014.

51. Oliveira-Nunes MC, Assad Kahn S, de Oliveira Barbeitas AL, TC ES, Dubois LG, Moura Neto V, Campanati L, Pereira CM, Freitas C, et al. Activation of the Hedgehog signal transduction network. Sci Signal. 2012;5:ra6.

52. Yam PT, Langlois SD, Morin S, Charon F. Sonic hedgehog guides axons through a noncanonical, Src-family-kinase-dependent signaling pathway. Neuron. 2009;62:349–62.

53. Polizio AH, Chinchilla P, Chen X, Kim S, Manning DR, Robo NA. Heterotrimeric Gi proteins link hedgehog signalling to activation of rho small GTPases to promote fibroblast migration. J Biol Chem. 2011;286:19889–96.

54. Belgacem YH, Borodinsky LN. Sonic hedgehog signalling is decoded by calcium spike activity in the developing spinal cord. Proc Natl Acad Sci U S A. 2011;108:4482–7.

55. Teperino R, Amann S, Bayer M, McGee SL, Loipetzberger A, Connor T, Jaeger C, Robbins DJ, Fei DL, Riobo NA. The hedgehog signal transduction network. Sci Signal. 2012;5:ra6.

56. Arensdorf AM, Marada S, Ogden SK. Smoothened regulation: a tale of two sides. Trends Pharmacol Sci. 2016;37:62–7.

57. Shevde LA, Samant RS. Nonclassical hedgehog-GLI signaling and its clinical implications. Int J Cancer. 2014;135:1–6.

58. Yan GN, Yang L, Lv YF, Shi Y, Shen LL, Yao XH, Guo QN, Zhang P, Cui YH, et al. Endothelial cells promote stem-like phenotype of glioma cells through activating the hedgehog pathway. J Pathol. 2014;234:1–22.

59. Robbins DJ, Fei DL, Riobo NA. The hedgehog signal transduction network. Sci Signal. 2012;5:ra6.

60. Seto M, Ohtta M, Asakura Y, Ikenour T, Tada M, Miyabayashi K, Mohi D, Tanaka Y, Iuchi H, Tateshii K, et al. Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer. Mol Carcinog. 2009;48:703–12.

61. Gotschel F, Berg D, Gruber W, Bender C, Eberl M, Fieder M, Sonntag J, Rungeler E, Hache H, Wierling C, et al. Synergism between hedgehog-GLI and EGF signaling in hedgehog-responsive human medulloblastoma cells induces downregulation of canonical hedgehog-target genes and stabilized expression of Gli1. PLoS One. 2013;8:e64903.

62. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Sonic hedgehog functions through dynamic changes in the side of the astrocyte. In: In: Glioma Cell Biology (Mentlein ASaR ed., vol. 1. Vienna: Springer Netherlands Vienna; 2014.

63. Domanska Adriaan M, Bokhoven Meine I, Sopoth TC, Porto-Carreiro I, Pereira CM, Balca-Silva J, Kahn SA, DosSantos MF, et al. Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci. 2014;8:418.

64. Moura Neto V, Campanati L, Pereira CM, Freitas C, Coelho-Aguiar J, Tavares AL, SPOHR TCS, Aguiar KA, Kahn SA, Matus O, et al. Glioblastoma: a hidden side of the astrocyte. In: Gliona Cell Biology (Mentlein ASaR ed., vol. 1. Vienna: Springer Netherlands Vienna; 2014.

65. Oliveira-Nunes MC, Assad Kahn S, de Oliveira Barbeitas AL, TC ES, Dubois LG, Moura Neto V, Campanati L, Pereira CM, Freitas C, et al. Activation of the Hedgehog signal transduction network. Sci Signal. 2012;5:ra6.

66. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2012;60:502–14.

67. Dubois LG, Campanati L, Rigby C, D’Andrea-Meira I, Spoth TC, Porto-Carreiro I, Pereira CM, Balca-Silva J, Kahn SA, DosSantos MF, et al. Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci. 2014;8:418.

68. Moura Neto V, Campanati L, Pereira CM, Freitas C, Coelho-Aguiar J, Tavares AL, SPOHR TCS, Aguiar KA, Kahn SA, Matus O, et al. Glioblastoma: a hidden side of the astrocyte. In: Gliona Cell Biology (Mentlein ASaR ed., vol. 1. Vienna: Springer Netherlands Vienna; 2014.

69. Oliveira-Nunes MC, Assad Kahn S, de Oliveira Barbeitas AL, TC ES, Dubois LG, Moura Neto V, Campanati L, Pereira CM, Freitas C, et al. Activation of the Hedgehog signal transduction network. Sci Signal. 2012;5:ra6.
93. Alves TR, Lima FR, Kahn SA, Lobo D, Dubois LG, Soletti R, Borges H, Neto VM. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci. 2011;89:532–9.
94. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
95. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, Kaina B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007;26:186–97.
96. Belinsky SA, Klinge DM, Liechty KC, March TH, Kang T, Gilliland FD, Sotnic N, Tas S, Avci O. Rapid clearance of psoriatic skin lesions induced by topical cyclopamine. A preliminary proof of concept study. Dermatology. 2004;209:126–31.
97. Srivenugopal KS, Ali-Osman F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene. 2002;21:5940–5.
98. Chen L, Wang Y, Liu F, Xu L, Peng F, Zhao N, Fu B, Zhu Z, Shi Y, Liu J, et al. A systematic review and meta-analysis: association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung cancer. Sci Rep. 2018;8:1439.
99. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009;101:124–31.
100. van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind VM. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci. 2011;89:532–9.
101. Bhattacharjee S, Nandi S. Synthetic lethality in DNA repair network: a novel pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007;25:2524–33.
102. Pistollato F, Abbadi S, Rampazzo E, Persano L, Della Puppa A, Frasson C, Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A, Eberhart CG. Cyclopamine-mediated hedgehog inhibition depletes stem-like cells in glioblastoma. Stem Cells. 2010;28:851–62.
103. Wang K, Chen D, Qian Z, Cui D, Gao L, Lou M. Hedgehog/Gli signaling regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma. Cancer Cell Int. 2017;17:117.
104. Cui D, Xu Q, Wang K, Che X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J Neurol Sci. 2010;288:156–66.
105. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007;26:574–9.
106. Sims-Mourtada J, Izzo JG, Aparisi-Manahanar S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute of tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006;12:5656–72.
107. Chen X, Horuchi A, Kikutchi N, Osada S, Chematiffy W, Bowers DC, Laughon S, Smith A, Gottardo NG, Partap S, Bendel A, Wright KD, et al. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 2017;8:69295–302.
108. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fas-1 expression. Proc Natl Acad Sci U S A. 2007;104:20350–5.
109. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez R, Macdonald TJ, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking hedgehog/GLI pathway. J Clin Invest. 2011;121:148–60.
110. Kunthekar P, Grimm S, Chandler J, Mehta M, Marymont M, Levy R, Muro K, Helenowski I, McCarthy K, Fountas L, Raiser J. A phase II trial of arsensic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. J Neuro-Oncol. 2017;133:589–94.
111. Matias D, Predes D, Niemeyer Filho P, Lopes MC, Abreu JG, Lima FR, Mora Neto V. Microgilla-glioblastoma interactions: new role for Wnt signaling. Biochim Biophys Acta. 2017;1868:333–40.
112. Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRCA and PIK3/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med. 2012;14:207–14.